(Q71120796)
Statements
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group (English)
R T Schooley
C Ramirez-Ronda
J M Lange
D A Cooper
J Lavelle
L Lefkowitz
M Moore
B A Larder
M St Clair
J W Mulder
R McKinnis
K N Pennington
P R Harrigan
I Kinghorn
H Steel